Personal tools

Coexpression cluster:C1724: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 6: Line 6:
|ontology_enrichment_disease=DOID:162!1.60e-23!235;DOID:14566!4.28e-22!239;DOID:0050686!1.34e-14!137;DOID:2531!4.55e-14!51;DOID:0060083!4.55e-14!51;DOID:1240!3.56e-13!39;DOID:0050687!4.41e-12!143;DOID:8692!2.77e-11!31;DOID:305!5.24e-10!106
|ontology_enrichment_disease=DOID:162!1.60e-23!235;DOID:14566!4.28e-22!239;DOID:0050686!1.34e-14!137;DOID:2531!4.55e-14!51;DOID:0060083!4.55e-14!51;DOID:1240!3.56e-13!39;DOID:0050687!4.41e-12!143;DOID:8692!2.77e-11!31;DOID:305!5.24e-10!106
|ontology_enrichment_uberon=
|ontology_enrichment_uberon=
|pathway_enrichment=4.41326987260908e-06;0.00279359982936155;2;25;{BCLAF1,25} (Static Module):NA
}}
}}

Revision as of 14:55, 13 July 2012


Full id: C1724_Mast_medulloblastoma_small_non_cerebellum_hepatoblastoma_merkel



Phase1 CAGE Peaks

Hg19::chr14:39644395..39644417,+p2@PNN
Hg19::chr14:39644425..39644470,+p1@PNN
Hg19::chr14:73525265..73525286,+p2@RBM25
Hg19::chr17:48796951..48796996,+p1@LUC7L3
Hg19::chr1:71546690..71546730,-p1@ZRANB2


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


p.valueFDRnGenesnPathwayName
4.41326987260908e-060.00279359982936155225{BCLAF1,25} (Static Module):NA



Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0008380RNA splicing2.07888694300519e-05
GO:0006397mRNA processing2.07888694300519e-05
GO:0016071mRNA metabolic process2.73085205460659e-05
GO:0006396RNA processing7.43177090078823e-05
GO:0016070RNA metabolic process0.029620301332372
GO:0003723RNA binding0.0328230854762404
GO:0003729mRNA binding0.0347091582755624
GO:0010467gene expression0.041196620178578
GO:0006139nucleobase, nucleoside, nucleotide and nucleic acid metabolic process0.041196620178578
GO:0000375RNA splicing, via transesterification reactions0.041196620178578
GO:0000398nuclear mRNA splicing, via spliceosome0.041196620178578
GO:0000377RNA splicing, via transesterification reactions with bulged adenosine as nucleophile0.041196620178578
GO:0003676nucleic acid binding0.041196620178578
GO:0016607nuclear speck0.0423044908580203



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br><br>disease_data<br>


Disease
Ontology termp-valuen
cancer1.60e-23235
disease of cellular proliferation4.28e-22239
organ system cancer1.34e-14137
hematologic cancer4.55e-1451
immune system cancer4.55e-1451
leukemia3.56e-1339
cell type cancer4.41e-12143
myeloid leukemia2.77e-1131
carcinoma5.24e-10106


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data


This analysis result is provided for C0 - C305 clusters.